Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy

• Jennifer Strong, BS,
• Vincent I. Poon, MD,
• Patrick Hallaert, BS,
• Deneise Francis, RN,
• Danielle M. Pastor, DO, PhD,
• Leslie Castelo-Soccio, MD, PhD,
• Julius Strauss, MD,
• Isaac Brownell, MD, PhD

Affiliations

Jennifer Strong, BS

Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland

Vincent I. Poon, MD

Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Patrick Hallaert, BS

Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland

Deneise Francis, RN

Office of Research Nursing, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland

Danielle M. Pastor, DO, PhD

Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Leslie Castelo-Soccio, MD, PhD

Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland

Julius Strauss, MD

Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Isaac Brownell, MD, PhD

Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland; Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Correspondence to: Isaac Brownell, MD, PhD, Dermatology Branch, NIAMS, NIH, 10 Center Dr, 12N240C, Bethesda, MD 20892-1908.